This price reduction is expected to save up to USD 22 million annually, enabling treatment for more people living with MDR-TB.

TBA-354 is the first potential tuberculosis drug to advance to Phase 1 trial in six years.

The TB Europe Coalition launches the Fight TB 2015 campaign to ensure that European leaders step up their response to TB to save millions of lives.

The deadline for submission is Friday, 24 April 2015.

Independent review recommends first steps to tackle drug-resistant superbugs.

Erica Lessem: Otsuka claims to have a compassionate use program, but there is nothing compassionate about only allowing a handful of patients to access delamanid.

The deadline for the submission of public comments on applications to be considered by the 20th Expert Committee on the Selection and Use of Essential medicines has been extended until Wednesday 25 February 2015.

The Annual Epidemiological Report 2014 for respiratory tract infections - tuberculosis provides a snapshot of the epidemiological situation of TB in Europe, featuring data from 2012.

Dr. Eric Goosby, the new UN Special Envoy on Tuberculosis, will work towards boosting the profile of the fight against TB and promoting the adoption, financing and implementation of the UN WHO’s global End TB Strategy after 2015.

Otsuka rejected Dr. Caitlin Reed’s attempt to obtain delamanid for her patient, Gary, who has the most drug-resistant case of TB ever identified in the United States.